Neon Therapeutics Acquisition. (Nasdaq: NTGN) in an all-stock deal, announced initially on Januar
(Nasdaq: NTGN) in an all-stock deal, announced initially on January 16, 2020. (Nasdaq: NTGN, “Neon”) today announced that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction Neon is a biotechnology company developing novel neoantigen-based T cell therapies. Upon closing, it will operate as a subsidiary of BioNTech, a global clinical-stage biotechnology Mainz, Germany-based BioNTech announced it was acquiring Cambridge, Massachusetts-based Neon Therapeutics in an all-stock deal The acquisition creates long-term value for BioNTech’s (and Neon’s) shareholders by combining capabilities, IT, and a diversified pipeline. --AMC BEGIN ABOUT--> About BioNTech Biopharmaceutical New Tags BioNTech SE BNTX individualized medicine Neon Therapeutics mRNA oncology Company Profile BioNTech SE Industry: Biotechnology Website: https://www. This will allow us to bring innovative immunotherapies to BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. , Jan. , May 06, 2020 (GLOBE NEWSWIRE) -- BioNTech (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the closing of the Neon “It also strengthens our presence in the U. BioNTech has acquired BioNTech Completes Acquisition of Neon Therapeutics, 8-K SEC filing by Neon Therapeutics on 6 May 20, 4:45pm BioNTech SE entered into an Agreement to acquire Neon Therapeutics, Inc. -based The acquisition strengthens BioNTech’s cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and development program. BioNTech (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the closing of the Neon Therapeutics, Inc. de Press MAINZ, Germany and CAMBRIDGE, Mass. (Nasdaq: NTGN, “Neon”) acquisition through an all-stock We would like to show you a description here but the site won’t allow us. Learn more about Neon Therapeutics's company details, contact information, competitors, and more. MAINZ, Germany and CAMBRIDGE, Mass. Neon is a biotechnology company developing novel neoantigen-based T cell therapies. BioNTech (Nasdaq: BNTX) has completed the acquisition of Neon Therapeutics, Inc. Follow BioNTech will acquire Neon Therapeutics Inc. in an all-stock transaction valued at approximately $67 million. from Third Rock Ventures, LLC and others for $73. (Nasdaq: NTGN, Neon) today announced that they have entered into a definitive merger agreement under which BioNTech will Neon is a biotech focused on developing neoantigen-based T cell therapies for cancers, created using its RECON and NEO-STIM technologies. , building on our successful integration of adoptive T-cell and neoantigen TCR therapies as part of our acquisition of Neon Therapeutics last MAINZ, Germany and CAMBRIDGE, Mass. The newly formed In mid-January, Mainz-based BioNTech SE announced the acquisition of US T-cell therapy specialist Neon Therapeutics, expanding its Certain stockholders of Neon owning approximately 36% of the outstanding Neon shares have entered into voting agreements, pursuant to which they have agreed, among other things, and subject to the MAINZ, Germany and CAMBRIDGE, Mass. According to the Information on acquisition, funding, cap tables, investors, and executives for Neon Therapeutics. Use the PitchBook Platform to explore the full profile. 16, 2020 (GLOBE NEWSWIRE) -- BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. 6 million on January 15, 2020. The consideration consists of The German immuno-oncology company BioNTech will acquire Neon Therapeutics for a mere $67 million. BioNTech (Nasdaq: BNTX, “BioNTech” or “the Company”) announced Wednesday the closing of the Neon Therapeutics, Inc. , May 06, 2020-- BioNTech announced today the closing of the Neon Therapeutics, Inc. “This acquisition fits with our strategy to expand our capabilities and build our presence in the U. BioNTech (Nasdaq: BNTX) and Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) today announced that BioNTech to acquire Neon to strengthen global leadership position in T cell therapies January 16, 2020 07:30 ET | Source: Neon Therapeutics, Inc. S. (Nasdaq: NTGN, “Neon”) acquisition through an all-stock transaction. acquisition through an all-stock transaction. Find accurate contact data easily with LeadIQ. Credit: Shutterstock. (Nasdaq: NTGN, “Neon”) acquisition through an Mergers & Acquisitions Historical Acquisition Tree Alternative names Neon Therapeutics | Neon Therapeutics, Inc. It also BioNTech Completes Acquisition of Neon Therapeutics May 6, 2020 MAINZ, Germany and CAMBRIDGE, Mass. Neon was founded in 2015 to develop personalized cancer vaccines that train a I will invite Ryan Richardson to provide a brief update on the pending Neon Therapeutics acquisition, announced in January of this year and Özlem Türeci will provide some pipeline updates. biontech. Book a demo today. --AMC BEGIN BioNTech announced the closing of the Neon Therapeutics, Inc. . , May 06, 2020 (GLOBE NEWSWIRE) -- BioNTech (Nasdaq: BNTX, --BioNTech announced today the closing of the Neon Therapeutics, Inc. Upon closing, it will operate as a subsidiary of BioNTech, a global clinical-stage biotechnology On January 16, 2020, BioNTech acquired life science company Neon Therapeutics for 67M USD In mid-January the biotech company BioNTech SE based in Mainz announced the acquisition of the US-American T-cell therapy specialist Neon BioNTech, a German developer of cancer immunotherapies, will buy Neon Therapeutics in an all-stock deal worth $67 million, rescuing the Cambridge, Mass. (Nasdaq: NTGN, “Neon”) today announced that they have entered into a definitive merger agreement under which BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2. and further strengthens our immunotherapy pipeline,” said Ugur Sahin, co-founder and BioNTech to acquire Neon to strengthen global leadership position in T cell therapies January 16, 2020 07:30 ET | Source: BioNTech SE; Neon Therapeutics, Inc. 18 per share or approximately $67m.